Document registry — page 34
Every document the Institute has published, 1,631 in total, with its identifier, type, certainty rating and review date.
Documents
-
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in type 1 diabetes (adjunct) over as stated in the parent protocol. The Institute holds no…
Very low22 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 1/2 study of LL-37 in wound healing randomising 34 participants over 4 weeks. Primary result: A dose-dependent…
Low21 Nov 2023 -
Single-arm open-label, phase 3 study of Dulaglutide in type 2 diabetes over open-label extension of the parent trial. The Institute holds no reported primary result for…
Very low21 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in cardiovascular and chronic kidney disease and type 2 diabetes over as stated in the parent…
Very low21 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low21 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Hexarelin in lean-mass preservation over 16 weeks. Primary result: Tachyphylaxis of the growth-hormone…
Low20 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in type 1 diabetes (adjunct) over as stated in the parent protocol. The Institute holds no…
Very low20 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Thymosin beta-4 in wound healing over as stated in the parent protocol. The Institute holds no reported…
Very low20 Nov 2023 -
Phase 1 ascending dose, phase 1 study of Orforglipron in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low19 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Thymosin beta-4 in wound healing over as stated in the parent protocol. The Institute holds no reported…
Very low19 Nov 2023 -
Single-arm open-label, phase 2 study of Ipamorelin in gastric emptying over open-label extension of the parent trial. The Institute holds no reported primary result for…
Very low18 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in prediabetes and obesity over as stated in the parent protocol. The Institute holds no…
Very low17 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low17 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low16 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Kisspeptin-10 in sexual dysfunction over as stated in the parent protocol. The Institute holds no reported…
Very low16 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Hexarelin in lean-mass preservation over as stated in the parent protocol. The Institute holds no reported…
Very low16 Nov 2023 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result…
Very low16 Nov 2023 -
Phase 1 ascending dose, phase 1 study of Kisspeptin-10 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low15 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide, oral in obesity randomising 667 participants over 68 weeks. Primary result: Mean change −15.1…
Moderate14 Nov 2023 -
Phase 1 ascending dose, phase 1 study of GHK-Cu in wound healing over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low14 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low14 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Hexarelin in lean-mass preservation over as stated in the parent protocol. The Institute holds no reported…
Very low13 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of SS-31 (elamipretide) in hfpef over as stated in the parent protocol. The Institute holds no reported…
Very low11 Nov 2023 -
Dose-finding, phase 2 study of Cagrilintide in obesity randomising 706 participants over 26 weeks. Primary result: Dose-dependent change to −10.8 % at 4.5 mg versus −3.0…
Moderate10 Nov 2023 -
Phase 1 ascending dose, phase 1 study of Thymosin beta-4 in cardiovascular over single and multiple dose. Primary result: Tolerated over the doses evaluated; no efficacy…
Very low09 Nov 2023 -
Randomised crossover, phase 2 study of Kisspeptin-10 in sexual dysfunction randomising 32 participants over single administration per period. Primary result: A change in…
Low09 Nov 2023 -
Phase 1 ascending dose, phase 1 study of Semaglutide in adolescent obesity over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low09 Nov 2023 -
Observational, phase 3 study of Semaglutide, oral in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low08 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in type 1 diabetes (adjunct) randomising 835 participants over 26 weeks. Primary result…
Moderate07 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in type 2 diabetes randomising 478 participants over 40 weeks. Primary result: Reduction of…
High06 Nov 2023 -
Observational, phase 3 study of Liraglutide in type 1 diabetes (adjunct) over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low06 Nov 2023 -
Single-arm open-label, phase 3 study of Teduglutide in mucosal barrier over open-label extension of the parent trial. The Institute holds no reported primary result for…
Very low06 Nov 2023 -
Phase 1 ascending dose, phase 1 study of Kisspeptin-10 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low03 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Larazotide acetate in mucosal barrier over as stated in the parent protocol. The Institute holds no…
Very low03 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low03 Nov 2023 -
Phase 1 ascending dose, phase 1 study of Cagrilintide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low31 Oct 2023 -
Randomised crossover, phase 1 study of Semaglutide in hfpef and obesity over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low31 Oct 2023 -
Phase 1 ascending dose, phase 1 study of Hexarelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low24 Oct 2023 -
Consultation on the rubric by which the Institute assesses a supplier dossier. The rubric scores documentary and analytical practice; it does not score product quality…
22 Oct 2023 -
Sterility testing of peptide preparations presented in sealed vials
High22 Oct 2023
page 34 of 41